摘要

BACKGROUND & AIMS:Little is known about the efficacy of H(2)-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers. We compared the efficacy of high-dose famotidine with that of pantoprazole in preventing recurrent symptomatic ulcers/erosions.
METHODS:We performed a randomized, double-blind, controlled trial of 160 patients with aspirin-related peptic ulcers/erosions, with or without a history of bleeding. Patients were given either famotidine (40 mg, morning and evening) or pantoprazole (20 mg in the morning and placebo in the evening). All patients continued to receive aspirin (80 mg daily). The primary end point was recurrent dyspeptic or bleeding ulcers/erosions within 48 weeks.
RESULTS:A total of 130 patients (81.1%) completed the study; 13 of 65 patients in the famotidine group reached the primary end point (20.0%; 95% one-sided confidence interval [CI] for the risk difference, 0.1184-1.0) compared with 0 of 65 patients in the pantoprazole group (P < .0001, 95% one-sided CI for the risk difference, 0.1184-1.0). Gastrointestinal bleeding was significantly more common in the famotidine group than the pantoprazole group (7.7% [5/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0226-1.0; P = .0289), as was recurrent dyspepsia caused by ulcers/erosions (12.3% [8/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0560-1.0; P = .0031). No patients had ulcer perforation or obstruction.
CONCLUSIONS:In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions.

译文

背景与目的: 关于 H (2) 受体拮抗剂在预防阿司匹林相关性消化性溃疡复发方面的疗效知之甚少。我们比较了大剂量法莫替丁和泮托拉唑预防复发症状性溃疡/糜烂的疗效。
方法: 我们对 160 名阿司匹林相关的消化性溃疡/糜烂患者进行了一项随机、双盲、对照试验,这些患者有或没有出血史。患者被给予法莫替丁 (40 毫克,早晚) 或泮托拉唑 (早上 20 毫克,晚上安慰剂)。所有患者继续接受阿司匹林 (每天 80 毫克)。主要终点是 48 周内复发的消化不良或出血溃疡/糜烂。
结果: 共有 130 名患者 (81.1%) 完成了研究; 法莫替丁组 65 名患者中有 13 名达到了主要终点 (20.0%; 95% 单侧置信区间 [CI] 为风险差异,0.1184-1.0),与泮托拉唑组 65 例患者的 0 相比 (P <。 0001风险差异的单侧 CI 为 95%,0.1184-1.0)。胃肠道出血在法莫替丁组明显比泮托拉唑组更常见 (7.7% [5/65] vs 0% [0/65]; 95% 风险差异的单侧 CI,0.0226-1.0; P =。 0289),以及由溃疡/糜烂引起的复发性消化不良 (12.3% [8/65] vs 0% [0/65];95% 风险差异的单侧 CI,0.0560-1.0; P =.0031)。无患者出现溃疡穿孔或阻塞。
结论: 在阿司匹林相关的消化性溃疡/糜烂患者中,大剂量法莫替丁治疗在预防复发性消化不良或出血溃疡/糜烂方面不如泮托拉唑。

Famotidine

消化 H2受体阻滞剂 药物
概述  :  

法莫替丁为第3代H2受体阻滞剂。主要用于治疗各种消化性溃疡和卓-艾综合征。由于其作用强、特异性高、耐受性好、起效快、毒性和副作用小等特点,迅速取代雷尼替丁和西咪替丁而成为抗消化性溃疡的最重要的药物,也是世界上最畅销的药物之一。法莫替丁制剂研究近年来取得很大的成果,其制剂品种越来越多。目前有片剂、胶囊剂、分散片等十多种。   药理 1)药效学:本药为高效、长效的呱基噻唑类H2受体阻滞药,具有对H2受体亲和力高的特点,其作用

Famotidine  英/feɪ'mɒtaɪdɪn/  美 /feɪ'mɒtaɪdɪn/

释    义   n.法莫替丁

例    句   To optimize dissolution determination of compound famotidine dispersibletablets. 建立复方法莫替丁分散片的溶出度测定方法.

请扫描右侧二维码,免费查看词汇专业知识背景